http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2711525-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faf81825084f39c08083a00cb863b2e8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-787 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-66 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-787 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-738 |
| filingDate | 2019-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_047c5bb7f344f50d79c232b3df94d4f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2e1c3d3491c60f4356afa364de9a358 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cc75cfd32552f026609b8fc802a6424 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5544ca268e77d5ccc022e96e811b26ab |
| publicationDate | 2020-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2711525-C1 |
| titleOfInvention | Method of treating patients with allergic rhinitis with disturbed microbe landscape of nasal mucosa |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and can be used for treating patients with allergic rhinitis with disturbed microbial landscape of nasal mucosa. That is ensured by a three-stage conservative therapy: at the first stage, administering the poly-oxidonium immunomodulator in tablet form 12 mg twice a day orally for 10 days according to scheme 1, 2, 4, 6, 8, 11, 14, 17, 20, 23 days, in accordance with the patient's immune system changes; at the second stage, from the fifth day from reception of polyoxidonium, on the basis of bacteriological research taking into account sensitivity the antibacterial therapy and elimination therapy by a preparation of dolphin 2 times a day is carried out for 10 days; at the third stage, after the course of the antibacterial and elimination therapy, Maxillac synbiotic is administered orally 1 capsule per day for 20 days and polyvalent bacteriophage 5 drops in each half of nose 3 times/day for 14 days. n EFFECT: method has a stable therapeutic effect with more complete recovery of nasal breathing and olfaction, reduced or disappearing intensity of paroxysmal sneezing attacks, rhinorrhea, manifestations of conjunctivitis and chronic sinusitis. n 1 cl, 7 tbl, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2760825-C1 |
| priorityDate | 2019-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 69.